David Rossi
30 Papers
219 Citations
David Rossi is an academic researcher. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 14, co-authored 30 publications.
Chat about Author
Papers
Mucinous Histology Predicts for Poor Response Rate and Overall Survival of Patients With Colorectal Cancer and Treated With First-Line Oxaliplatin- And/or Irinotecan-Based Chemotherapy
Vincenzo Catalano,Fotios Loupakis,Francesco Graziano,U. Torresi,R. Bisonni,D. Mari,Lorenzo Fornaro,Anna Maria Baldelli,Paolo Giordani,David Rossi,Paolo Alessandroni,Lucio Giustini,R. R. Silva,Alfredo Falcone,S. Demidio,S. L. Fedeli +15 more
TL;DR: It is shown that patients with mucinous colorectal cancer have poor responsiveness to oxaliplatin/irinotecan-based first-line combination chemotherapy and an unfavourable prognosis compared with non-mucinous colorean cancer patients.
Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?
Vincenzo Catalano,Francesco Graziano,Daniele Santini,S. Demidio,Anna Maria Baldelli,David Rossi,Bruno Vincenzi,Paolo Giordani,Paolo Alessandroni,E. Testa,Giuseppe Tonini,Giuseppina Catalano +11 more
TL;DR: The influence of clinico-pathologic factors on the survival of 175 advanced gastric cancer patients, who received second-line chemotherapy at three oncology departments, is evaluated.
•Journal Article
Chemoembolization in colorectal liver metastases: The rebirth
Giammaria Fiorentini,Camillo Aliberti,Luca Mulazzani,Paolo Coschiera,Vincenzo Catalano,David Rossi,Paolo Giordani,Stefano Ricci +7 more
TL;DR: The understanding that hypoxia induces vessel re-growth will open a new avenue for clinical research and a rebirth for TACE, and the development of new embolizing agents permits better standardization and definition of protocols, making the procedures less linked to criteria of different hospitals and personal experiences of interventional radiologists.
54
Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
David Rossi,Paolo Alessandroni,Vincenzo Catalano,Paolo Giordani,Stephano Luzi Fedeli,Anna Fedeli,Anna Maria Baldelli,Virginia Casadei,Monica Ceccolini,Giuseppina Catalano +9 more
TL;DR: A lower dose of capecitabine has a good toxicity profile and is active in patients with MBC, and this study confirmed that the drug enables chronic dosing that mimics continuous infusion of 5-FU.
39
Neoadjuvant chemotherapy with low dose of pegylated liposomal doxorubicin plus weekly paclitaxel in operable and locally advanced breast cancer.
David Rossi,Anna Maria Baldelli,Virginia Casadei,Stefano Luzi Fedeli,Paolo Alessandroni,Vincenzo Catalano,Paolo Giordani,Monica Ceccolini,Francesco Graziano,Giuseppina Catalano +9 more
TL;DR: The combination of biweekly PLD and weekly paclitaxel was active in operable and locally advanced breast cancer with a manageable safety profile.
34